Skip to search formSkip to main contentSkip to account menu

F 16618

Known as: F-16618, F16618 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase‐activated receptor‐1 (PAR1) antagonist
BACKGROUND AND PURPOSE New antithrombotic agents with the potential to prevent atherothrombotic complications are being developed… 
2011
2011
Protease-Activated Receptor-1 Antagonist F 16618 Reduces Arterial Restenosis by Down-Regulation of Tumor Necrosis Factor α and Matrix Metalloproteinase 7 Expression, Migration, and Proliferation of…
Wound healing after angioplasty or stenting is associated with increased production of thrombin and the activation of protease… 
2010
2010
Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat.
2009
2009
The Novel Protease-Activated Receptor Type-1 Antagonist, F16618, Reduces Thrombus Formation in a Clinical Model of Thrombosis
2009
2009
Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)